What is acute lymphoblastic leukemia?
ALL develops when immature lymphoid cells, called lymphoblasts, grow without normal control. The abnormal cells can replace healthy marrow, reducing red cells, functional white cells, and platelets, and may reach lymph nodes, liver, spleen, central nervous system, or other sites. Most cases arise from B-cell precursors; a smaller group has T-cell lineage. ALL is the most common leukemia in children but also affects adults, whose disease biology and treatment tolerance may differ. It usually worsens quickly without treatment. Risk factors are not found in most people; recognized associations include certain inherited syndromes and prior chemotherapy or high-dose radiation exposure. Classification increasingly incorporates chromosome and gene findings because changes such as BCR::ABL1 can direct therapy. Care depends on whether ALL is newly diagnosed, in remission, or recurrent, its lineage and biomarkers, central nervous system involvement, measurable residual disease, age, and general health.
Signs and symptoms
ALL can produce symptoms as leukemia cells crowd normal marrow or collect in tissues. Possible findings include fatigue, weakness, pale skin, shortness of breath, fever, drenching night sweats, repeated infections, easy bruising, prolonged bleeding, nosebleeds, or pinpoint red spots under the skin. Bone or abdominal pain, reduced appetite, unexplained weight loss, and fullness below the ribs can occur. Painless lumps may appear in the neck, underarm, abdomen, or groin. Headache, vomiting, vision changes, or neurologic symptoms may occur if the central nervous system is involved, although these are not unique to ALL. Symptoms can arise over a short period. These signs and symptoms can also be caused by viral illnesses, anemia, medication effects, immune conditions, and other noncancer problems. Prompt medical evaluation is appropriate for persistent fever, unusual bleeding, severe weakness, or other concerning changes.
Diagnosis and staging
Testing usually begins with a complete blood count, differential, blood chemistry, and peripheral smear. Bone marrow aspiration and biopsy establish the diagnosis and quantify blasts. Flow cytometry or immunophenotyping determines B-cell or T-cell lineage and distinguishes ALL from other blood cancers. Cytogenetic, fluorescence in situ hybridization, and molecular studies identify chromosome and gene changes, including the Philadelphia chromosome or BCR::ABL1, that affect risk and targeted therapy. A lumbar puncture checks cerebrospinal fluid for leukemia cells; imaging may be used when symptoms suggest organ or tissue involvement. ALL does not use a standard stage I–IV system. It is described as untreated, in remission, measurable residual disease positive or negative, refractory, or recurrent, with central nervous system status and biologic risk features documented. Response testing during and after therapy is central to planning. Interpretation and care depend on lineage, disease status, biomarkers, age, treatment response, and overall health.
Established treatment paths
ALL treatment usually begins promptly and is delivered in phases. Remission induction uses combination chemotherapy, often with corticosteroids, to reduce leukemia cells. Consolidation or intensification follows remission to treat remaining disease, and maintenance therapy is used in many protocols. Central nervous system prophylaxis is generally included through intrathecal chemotherapy, systemic drugs that reach the cerebrospinal fluid, and selected use of radiation. Philadelphia chromosome–positive ALL is treated with a BCR::ABL1 tyrosine kinase inhibitor combined with an ALL regimen. Antibody-based therapies such as blinatumomab or inotuzumab may be used in defined settings, and CAR T-cell therapy is available for some relapsed or refractory B-cell ALL. Allogeneic stem cell transplantation may be considered for high-risk, persistent, or recurrent disease. Pediatric-inspired regimens may be used for adolescents and young adults when appropriate. Choices depend on B- or T-cell lineage, molecular biomarkers, measurable residual disease, central nervous system involvement, prior therapy, age, organ function, and treatment goals. Clinical trials may offer access to evolving strategies. Repeat marrow and measurable residual disease results can intensify, reduce, or redirect later treatment phases.
Supportive care
Supportive care may include red-cell or platelet transfusions, antibiotics or antifungal medicines, nausea control, pain relief, mouth care, and nutrition support. Teams monitor closely for infection, bleeding, tumor lysis syndrome, liver or heart effects, neuropathy, blood clots, and complications of corticosteroids or immune therapies. Fever during treatment may require urgent evaluation. Fertility preservation should be discussed before therapy when feasible, and children and adolescents may need school, developmental, and family support. Rehabilitation, mental health care, and palliative care can help with symptoms and quality of life throughout treatment. Follow-up includes response testing and surveillance for recurrence and late effects. Medicines, vaccines, and supplements should be reviewed with the leukemia team.
Profiles documenting acute lymphoblastic leukemia care
These profiles mention a matching cancer specialty in their published materials. Browse their locations, reported services, and practical details.
Sources
Source information checked: 2026-09-29. The links below identify the public and clinic-provided materials used for this page.
- NCI: Acute Lymphoblastic Leukemia Treatment ↗Checked 2026-09-29
- NCI: Childhood Acute Lymphoblastic Leukemia ↗Checked 2026-09-29
How Cancer Clinic Finder compiles information · Suggest a factual correction
